Trials / Completed
CompletedNCT03382431
A Study of PC786 to Evaluate the Antiviral Activity, Safety and Pharmacokinetics of Multiple Doses in an RSV Challenge Study
A Single-blind, Placebo Controlled, Randomised Study to Evaluate Antiviral Activity and Safety and Pharmacokinetics of Inhaled PC786 Against Respiratory Syncytial Virus (RSV) in Healthy Adult Subjects in a Virus Challenge Model
- Status
- Completed
- Phase
- Phase 1 / Phase 2
- Study type
- Interventional
- Enrollment
- 56 (actual)
- Sponsor
- Pulmocide Ltd · Industry
- Sex
- All
- Age
- 18 Years – 55 Years
- Healthy volunteers
- Accepted
Summary
PC786 is a new medicine being developed for treatment of respiratory syncytial virus. The main purpose of this study is to evaluate the antiviral activity of PC786 in healthy adults infected with RSV virus in a viral challenge study.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | PC786 | Repeat doses |
| DRUG | Placebo/vehicle | Repeat doses |
Timeline
- Start date
- 2017-11-14
- Primary completion
- 2018-05-09
- Completion
- 2018-05-09
- First posted
- 2017-12-22
- Last updated
- 2018-05-16
Locations
1 site across 1 country: United Kingdom
Source: ClinicalTrials.gov record NCT03382431. Inclusion in this directory is not an endorsement.